Access the science, technology and contacts that you need to accelerate your biologics and novel products towards commercial success.

Bioprinting capabilities and futures

Share this article

Bioprinting is ready to create tissue products with high commercial and therapeutic value, but engineered organs are still to come. Early investors are jumping in while Big Pharma moves bioprinting companies in house, new players enter the field, and stakeholders are collaborating at entry level. Government agencies are committing extensive resources to the technology, with regulators preparing to handle bioprinted products.

In this in-depth article in BioProcess International, authors from Charles River Associates talk about the need to  negotiate key development hurdles to make this technology viable for the biopharmaceutical industry.

Read the full article here...

Share this article

Upcoming event

BioProcess International Europe

28 Apr - 01 May 2020, Amsterdam
Europe’s Leading BioProcessing Event for Accelerating Biologics, mAbs, Vaccines and Novel Products to Commercial Success
Go to site